Biomarkers for trials of neuroprotection in Parkinson's disease

Movement Disorders

Volumn 28, Issue 1, 2013, Pages 71-85

  Agarwal, Pankaj A ^a   Stoessl, A Jon ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Vancouver Costal Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BIOLOGICAL MARKER; EPIDEPRIDE; FALLYPRIDE F 18; IOLOPRIDE I 123; ISOREMOXIPRIDE; LEVODOPA; MOLECULAR MARKER; PRAMIPEXOLE; RACLOPRIDE C 11; TRACER; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; ENERGY METABOLISM; ESSENTIAL TREMOR; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; DOPAMINE; ESSENTIAL TREMOR; HUMANS; NEUROIMAGING; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84873415220     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25065     Document Type: Review

References (161)

1. de Rijk MC, Launer LJ, Berger K, Breteler MMB, Dartigues JF, Baldereschi M et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000;54:S21-S23.
2. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
3. Bernheim H, Birkmaye W, Hornykie O, Jellinge K, Seitelbe F. Brain dopamine and syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
4. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
5. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
6. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
7. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
8. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
9. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
10. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542.
11. Sossi V, Fuente-Fernandez R, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002;22:232-239.
12. Doudet DJ, Chan GL, Holden JE, et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998;29:225-232.
13. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. J Nucl Med 1997;38:630-636.
14. Doudet DJ, Chan GLY, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab 1999;19:278-287.
15. Jordan S, Eberling JL, Bankiewicz KS, et al. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine lesions in primates. Brain Res 1997;750:276.
16. Christine CW, Starr A, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-1669.
17. Gallagher CL, Christian BT, Holden JE, et al. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease. Mov Disord 2011;26:2032-2038.
18. Moore RY, Whone AL, McGowan S, Brooks DJ. Monoamine neuron innervation of the normal human brain: an F-18-DOPA PET study. Brain Res 2003;982:137-145.
19. Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ. [(18)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(18)F]FDOPA and [(11)C]DASB PET study in Parkinson's disease. Neuroimage 2012;59:1080-1084.
20. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 1997;388:211-227.
21. Nirenberg MJ, Chan J, Liu YJ, Edwards RH, Pickel VM. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 1996;16:4135-4145.
22. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
23. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003;18:S43-SS51.
24. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
25. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [F-18]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604-1609.
26. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-β CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38:1453-1459.
27. Volkow ND, Ding YS, Fowler JS, et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995;36:2162-2168.
28. Vanderborght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [H-3]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-962.
29. Vanderborght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
30. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16:3507-3510.
31. de la Fuente-Fernandez R, Furtado S, Guttman M, et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 2003;49:20-28.
32. Fuente-Fernandez R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 2009;63:713-716.
33. Boileau I, Rusjan P, Houle S, et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 2008;28:9850-9856.
34. Tong JC, Wilson AA, Boileau I, Houle S, Kish SJ. Dopamine modulating drugs influence striatal (+)-[(11)C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008;62:873-876.
35. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
36. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
37. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
38. de Paulis T. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. Curr Pharm Des 2003;9:673-696.
39. Pinborg LH, Videbaek C, Ziebell M, et al. [I-123]epidepride binding to cerebellar dopamine D-2/D-3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage 2007;34:1450-1453.
40. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D-2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [C-11]raclopride. Mov Disord 1997;12:33-38.
41. 11C]N-methylspiperone. J Nucl Med 2000;41:65-70.
42. Thobois S, Vingerhoets F, Fraix V, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 2004;61:1705-1709.
43. Rinne JO, Laihinen A, Nagren K, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 1990;27:494-499.
44. Ma YL, Tang CK, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
45. Eckert T, Van Laere K, Tang CK, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007;34:496-501.
46. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006;129:2667-2678.
47. Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005;2:361-371.
48. Ma Y, Huang C, Dyke JP, et al. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010;30:505-509.
49. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
50. Piccini P, Burn DJ, Ceravolo R, Maraganore DM, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-582.
51. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128:2777-2785.
52. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008;71:1790-1795.
53. Sossi V, Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010;25:2717-2723.
54. Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005;64:134-136.
55. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849-853.
56. Ponsen MM, Stoffers D, Booij J, Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
57. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
58. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-1202.
59. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-1300.
60. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000;55:1410-1412.
61. Iranzo A, Valldeoriola F, Lomena F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
62. Stockner H, Iranzo A, Seppi K, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009;24:1906-1909.
63. Scherfler C, Frauscher B, Schocke M, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011;69:400-407.
64. Unger MM, Belke M, Menzler K, et al. Diffusion Tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010;33:767-773.
65. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-2215.
66. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009;80:744-748.
67. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord 2010;25:560-569.
68. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006;27:933-937.
69. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Successful antiparkinsonian medication withdrawal in patients with parkinsonism and normal FP-CIT SPECT. Mov Disord 2006;21:2247-2250.
70. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
71. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
72. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187-2195.
73. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-921.
74. Eckert T, Van Laere K, Tang CK, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007;34:496-501.
75. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010;30:1049-1056.
76. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527.
77. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [F-18]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-274.
78. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-158.
79. Benamer HTS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [I-123]-FP-CIT SPECT imaging: the [I-123]-FP-CIT study group. Mov Disord 2000;15:503-510.
80. Benaderette S, Zanotti Fregonara P, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord 2006;21:310-317.
81. Felicio AC, Godeiro C, Moriyama TS, et al. Degenerative parkinsonism in patients with psychogenic parkinsonism: a dopamine transporter imaging study. Clin Neurol Neurosurg 2010;112:282-285.
82. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-67.
83. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
84. Marek KL, Seibyl JP, Zoghbi SS, et al. [I-123] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
85. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132:2970-2979.
86. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009;24:1009-1015.
87. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53:S61-S70.
88. Muchowskil PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 2002;35:9-12.
89. Schapira AHV, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44:S89-S98.
90. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [F-18]CFT PET. Synapse 2003;48:109-115.
91. Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994;117:509-516.
92. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
93. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [F-18] dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
94. Fuente-Fernandez R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011;69:803-810.
95. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011;134:3290-3298.
96. Huang CR, Tang CK, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-1846.
97. Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006;31:301-307.
98. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 2000;23:34-44.
99. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
100. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch Neurol 1999;56:529-535.
101. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
102. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001;50:181-187.
103. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
104. Stoessl AJ. Agonizing over dopaminergic replacement therapy-lessons from animal models of Parkinson's disease. Exp Neurol 2003;183:1-3.
105. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
106. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
107. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761-765.
108. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689-695.
109. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of AAV-GAD gene therapy for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-2105.
110. Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:19559-19564.
111. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
112. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in parkinson's disease using diffusion tensor imaging. Mov Disord 2012;27:90-97.
113. Martin WRW, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-1417.
114. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433.
115. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia-nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
116. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-1031.
117. Berg D, Metz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
118. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-215.
119. Stoessl AJ. Functional imaging studies of non-motoric manifestations of Parkinson's Disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S13-S16.
120. Hong Z, Shi M, Chung KA, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713-726.
121. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
122. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240.
123. El Agnaf OMA, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
124. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772.
125. Hoepken HH, Gispert S, Azizov M, et al. Parkinson patient fibroblasts show increased α-synuclein expression. Exp Neurol 2008;212:307-313.
126. Shi M, Furay AR, Sossi V, Aasly JO, et al. DJ-1 and aSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012;33:836.e5-7.
127. Montine TJ, Shi M, Quinn JF, et al. CSF A beta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-2685.
128. Compta Y, Ezquerra M, Munoz E, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal beta-amyloid in Parkinson disease. Neurosci Lett 2011;487:169-173.
129. Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amyloid ß and tau in LRRK2 mutation carriers. Neurology 2012;78:55-61.
130. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69:655-663.
131. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526-529.
132. Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26:1428-1435.
133. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-567.
134. Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord 2008;23:1653-1657.
135. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65:716-723.
136. Ascherio A, Lewitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-1468.
137. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389-396.
138. Schwarzschild MA, Marek K, Eberly S, et al. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord 2011;26:1864-1868.
139. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 2005;64:1081-1083.
140. Ihara Y, Chuda M, Kuroda S, Hayabara T. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J Neurol Sci 1999;170:90-95.
141. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 2007;58:78-83.
142. Sohmiya M, Tanaka M, Tak NW, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004;223:161-166.
143. Isobe C, Murata T, Sato C, Terayama Y. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. J Clin Neurosci 2007;14:340-343.
144. Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999;14:141-147.
145. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008;167:90-95.
146. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009;119:332-337.
147. Moran LB, Graeber MB. Pathways of Parkinson's disease. Neuropathol Appl Neurobiol 2008;34:15.
148. Sutherland GT, Matigian NA, Chalk AM, et al. A cross-study transcriptional analysis of Parkinson's disease. PLoS One 2009;4:e4955.
149. Grünblatt E, Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer P. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm 2010;117:1387-1393.
150. Licker V, Kövari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson's disease research. J Proteomics 2009;73:10-29.
151. Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999;53:1488-1494.
152. Jin JH, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 2006;5:1193-1204.
153. Pan S, Rush J, Peskind ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 2008;7:720-730.
154. Li YH, Wang JA, Zheng XL, et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in Parkinson's disease. Eur Neurol 2011;65:105-111.
155. Zhao X, Xiao WZ, Pu XP, Zhong LJ. Proteome analysis of the sera from Chinese Parkinson's disease patients. Neurosci Lett 2010;479:175-179.
156. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004;22:245-252.
157. Ahmed SSSJ, Santosh W, Kumar S, Christlet HTT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 2009;16.
158. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. Plos One 2009;4:e7551.
159. Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
160. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001.
161. Eckert T, Tong C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-932.